NCT06373081View on ClinicalTrials.gov

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

NARecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2026

Conditions
Systemic Lupus Erythematosus (SLE)Sjogren's SyndromeSystemic SclerosisInflammatory MyopathyANCA Associated VasculitisAntiphospholipid Syndrome
Interventions
BIOLOGICAL

Anti-CD19-CD3E-CAR-T cells

The injection of anti-CD19-CD3E chimeric antigen receptor T (CAR-T) cells, referred to as anti-CD19-CD3E-CAR-T cells. The anti-CD19-CD3E-CAR protein is composed of a murine-derived CD19 single-chain variable fragment (scFv) FMC63, CD28 hinge and transmembrane regions, the intracellular domain of CD3E, the intracellular domain of CD28, and the intracellular domain of CD3ζ, all linked in sequence.

Trial Locations (1)

200003

RECRUITING

Shanghai ChangZheng hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER